EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Paclitaxel compromises nuclear integrity in interphase through SUN2-mediated cytoskeletal coupling

Thomas Hale iD, Victoria L Hale iD, Piotr Kolata, Ália Dos Santos iD, Matteo Allegretti iD

Journal of Cell Science · 2026

DOI: 10.1242/jcs.264494 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cell Science, 2026. Verfasst von Thomas Hale und 4 weiteren Autor:innen. Beteiligte Einrichtung: Structural Studies Division, MRC Laboratory of Molecular Biology, Cambridge CB2 0QH, UK. Hauptthemen laut MEDLINE: Paclitaxel, Interphase, Cytoskeleton, Cell Nucleus. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Medical Research Council, Medical Research Council Laboratory of Molecular Biology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Regulation of lamin A/C levels and distribution is crucial for nuclear integrity and mechanotransduction via the linker of nucleoskeleton and cytoskeleton (LINC) complex. Dysregulation of lamin A/C correlates with poor cancer prognosis, and its levels determine sensitivity to the microtubule-stabilising drug paclitaxel. Paclitaxel is well-known for disrupting mitosis, yet it also reduces tumour size in slow-dividing tumours, indicating an additional, poorly characterised interphase mechanism. Here, we reveal that paclitaxel induces nuclear aberrations in interphase through SUN2-dependent lamin A/C disruption. Using advanced optical imaging and electron cryo-tomography, we show the formation of aberrant microtubule–vimentin bundles during paclitaxel treatment, which coincides with nuclear deformation and altered lamin A/C protein levels and organisation at the nuclear envelope. SUN2 is required for lamin A/C reduction upon paclitaxel treatment and is in turn regulated by polyubiquitylation. Furthermore, lamin A/C expression levels determine not only cell survival during treatment but also recovery after drug removal. Our findings support a model in which paclitaxel acts through both defective mitosis and interphase nuclear–cytoskeletal disruption, providing additional mechanistic insights into a widely used anticancer drug.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PaclitaxelInterphaseCytoskeletonCell NucleusMembrane ProteinsIntracellular Signaling Peptides and ProteinsHumansLamin Type AMicrotubulesNuclear EnvelopeMitosisHeLa Cells

Stichwörter der Autor:innen

CancerLINCLamin A/CNucleusSUN2

Substanzen

PaclitaxelSUN2 protein, humanLamin Type AMembrane ProteinsIntracellular Signaling Peptides and Proteins

Autor:innen und Institutionen

  • Structural Studies Division, MRC Laboratory of Molecular Biology, Cambridge CB2 0QH, UK.

ORCID-Profile: Thomas Hale, Victoria L Hale, Ália Dos Santos, Matteo Allegretti

Förderung

  • Wellcome Trust
  • Medical Research Council
  • Medical Research Council Laboratory of Molecular Biology

Zitieren

APA

Hale, T., Hale, V. L., Kolata, P., Dos Santos, Á., & Allegretti, M. (2026). Paclitaxel compromises nuclear integrity in interphase through SUN2-mediated cytoskeletal coupling. Journal of Cell Science. https://doi.org/10.1242/jcs.264494

Vancouver

Hale T, Hale VL, Kolata P, Dos Santos Á, Allegretti M. Paclitaxel compromises nuclear integrity in interphase through SUN2-mediated cytoskeletal coupling. Journal of Cell Science. 2026. doi:10.1242/jcs.264494

BibTeX
@article{Hale2026,
  author = {Hale, Thomas and Hale, Victoria L and Kolata, Piotr and Dos Santos, Ália and Allegretti, Matteo},
  title = {Paclitaxel compromises nuclear integrity in interphase through SUN2-mediated cytoskeletal coupling},
  journal = {Journal of Cell Science},
  year = {2026},
  doi = {10.1242/jcs.264494}
}
Kostenlos starten →